Trial reportPloS one2010
Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants.
Trial report in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00158574 (Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine), which is not on this map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Intermittent preventive treatment for malaria in infants.The Cochrane database of systematic reviews · 2021Pooled it
- Intermittent preventive treatment for malaria in infants.The Cochrane database of systematic reviews · 2019Pooled it
- Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review.BMC medical informatics and decision making · 2012Pooled it
- A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc).PloS one · 2011Pooled it
- A Randomized Trial to Compare the Safety, Tolerability, and Effectiveness of 3 Antimalarial Regimens for the Prevention of Malaria in Nigerian Patients With Sickle Cell Disease.The Journal of infectious diseases · 2015Trial
- Cluster-randomized study of intermittent preventive treatment for malaria in infants (IPTi) in southern Tanzania: evaluation of impact on survival.Malaria journal · 2011Trial
- Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial.BMJ (Clinical research ed.) · 2011Trial
- Trial
- Trial
- Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children.Antimicrobial agents and chemotherapy · 2010Trial
- The Evolving Landscape of Malaria Prevention Strategies: A Review of Recent Developments.Pathogens (Basel, Switzerland) · 2026Review
- Impact of dhps mutations on sulfadoxine-pyrimethamine protective efficacy and implications for malaria chemoprevention.Nature communications · 2025Article
- Making the most of malaria chemoprevention.Malaria journal · 2024Review
- Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa.Malaria journal · 2015Article
- Submicroscopic malaria infection during pregnancy and the impact of intermittent preventive treatment.Malaria journal · 2014Observational
- Article
- Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum.European journal of drug metabolism and pharmacokinetics · 2011Article
- Article
- Follow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infants.The Journal of infectious diseases · 2011Article
- Intermittent preventive treatment to reduce the burden of malaria in children: new evidence on integration and delivery.PLoS medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundIntermittent preventive treatment in infants (IPTi) is a new malaria control tool. However, it is uncertain whether IPTi works mainly through chemoprophylaxis or treatment of existing infections. Understanding the mechanism is essential for development of replacements for sulfadoxine-pyrimethamine (SP) where it is no longer effective. This study investigated how protection against malaria given by SP, chlorproguanil-dapsone (CD) and mefloquine (MQ), varied with time since administration of IPTi. METHODS AND
findingsA secondary analysis of data from a randomised, placebo-controlled trial in an area of high antifolate resistance in Tanzania was conducted. IPTi using SP, CD, MQ or placebo was given to 1280 infants at 2, 3 and 9 months of age. Poisson regression with random effects to adjust for potential clustering of malaria episodes within children was used to calculate incidence rate ratios for clinical malaria in defined time strata following IPTi. The short-acting antimalarial CD gave no protection against clinical malaria, whereas long-acting MQ gave two months of substantial protection (protective efficacy (PE) 73.1% (95% CI: 23.9, 90.5) and 73.3% (95% CI: 0, 92.9) in the first and second month respectively). SP gave some protection in the first month after treatment (PE 64.5% (95% CI: 10.6, 85.9)) although it did not reduce the incidence of malaria up to 12 months of age. There was no evidence of either long-term protection or increased risk of malaria for any of the regimens.
conclusionPost-treatment chemoprophylaxis appears to be the main mechanism by which IPTi protects children against malaria. Long-acting antimalarials are therefore likely to be the most effective drugs for IPTi, but as monotherapies could be vulnerable to development of drug resistance. Due to concerns about tolerability, the mefloquine formulation used in this study is not suitable for IPTi. Further investigation of combinations of long-acting antimalarials for IPTi is needed.
trial registrationClinicaltrials.gov NCT00158574.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.